ECSP11011246A - Métodos para reducir la proliferación y viabilidad de los agentes microbianos - Google Patents

Métodos para reducir la proliferación y viabilidad de los agentes microbianos

Info

Publication number
ECSP11011246A
ECSP11011246A EC2011011246A ECSP11011246A ECSP11011246A EC SP11011246 A ECSP11011246 A EC SP11011246A EC 2011011246 A EC2011011246 A EC 2011011246A EC SP11011246 A ECSP11011246 A EC SP11011246A EC SP11011246 A ECSP11011246 A EC SP11011246A
Authority
EC
Ecuador
Prior art keywords
viability
proliferation
reduce
methods
microbial agents
Prior art date
Application number
EC2011011246A
Other languages
English (en)
Inventor
William Henry
Henk Andre Kroon
Linda Summerton
Original Assignee
Targeted Delivery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011246(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targeted Delivery Technologies Ltd filed Critical Targeted Delivery Technologies Ltd
Publication of ECSP11011246A publication Critical patent/ECSP11011246A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención se relaciona con formulaciones de un agente antimicrobiano, un lípido y, opcionalmente, un surfactante, y los usos de las mismas para reducir la proliferación y viabilidad de los agentes microbianos.
EC2011011246A 2009-02-05 2011-08-04 Métodos para reducir la proliferación y viabilidad de los agentes microbianos ECSP11011246A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15028809P 2009-02-05 2009-02-05

Publications (1)

Publication Number Publication Date
ECSP11011246A true ECSP11011246A (es) 2011-11-30

Family

ID=41460484

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011246A ECSP11011246A (es) 2009-02-05 2011-08-04 Métodos para reducir la proliferación y viabilidad de los agentes microbianos

Country Status (19)

Country Link
US (2) US20100197621A1 (es)
EP (1) EP2393480A1 (es)
JP (1) JP2012516889A (es)
KR (1) KR20110128283A (es)
CN (1) CN102368998A (es)
AU (1) AU2009339445A1 (es)
BR (1) BRPI0924302A2 (es)
CA (1) CA2751412A1 (es)
CO (1) CO6410285A2 (es)
CR (1) CR20110409A (es)
EC (1) ECSP11011246A (es)
IL (1) IL214331A0 (es)
MX (1) MX2011008204A (es)
NI (1) NI201100152A (es)
PE (1) PE20120326A1 (es)
RU (1) RU2011136624A (es)
SG (1) SG173183A1 (es)
WO (1) WO2010090654A1 (es)
ZA (1) ZA201105758B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
US9040539B2 (en) 2010-05-19 2015-05-26 Sandoz Ag Process for the preparation of chiral triazolones
CN102892762B (zh) 2010-05-19 2016-04-20 桑多斯股份公司 制备泊沙康唑中间体
EP2571847B1 (en) 2010-05-19 2016-09-21 Sandoz AG Process for the preparation of chiral hydrazides
RU2585683C2 (ru) 2010-05-19 2016-06-10 Сандоз Аг Очистка позаконазола и промежуточных продуктов для синтеза позаконазола
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
ES2565353T3 (es) 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
AU2012229068B2 (en) * 2011-03-15 2015-09-03 Thompson Cooper Laboratories, Llc Compositions and methods for treatment of infections
EP2688554A2 (en) * 2011-03-21 2014-01-29 Gregor Cevc Optimised preparations of highly adaptable aggregates
DK2701684T3 (en) 2011-04-28 2017-09-18 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use
CN103635465A (zh) 2011-06-16 2014-03-12 桑多斯股份公司 制备手性化合物的方法
WO2013043830A1 (en) * 2011-09-20 2013-03-28 Molecular Express, Inc. Nanoparticle formulations of poorly soluble compounds
KR101350442B1 (ko) * 2011-10-12 2014-01-15 김동진 클로르헥시딘을 함유하는 안정한 수용성 살균방부제 조성물
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CN102659734B (zh) * 2012-04-28 2014-07-16 山东大学 一种三烯抗生素的制备方法
US20150164890A1 (en) * 2012-06-14 2015-06-18 Sandoz Ag Pharmaceutical compositions comprising crystalline posaconazole
US20150250808A1 (en) 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
US8815952B1 (en) 2013-03-15 2014-08-26 Carnell & Herzog, LLC Chlorhexadine antiseptic
JP6206907B2 (ja) * 2013-07-16 2017-10-04 株式会社ゲノム創薬研究所 抗菌活性促進剤及び該抗菌活性促進剤を含有する感染症治療薬
AU2014329421B2 (en) * 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
JP6611014B2 (ja) 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置
CN103690543B (zh) * 2013-12-24 2015-09-09 广西医科大学 杀死烟曲霉菌的组合物及方法
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
CN106546668A (zh) * 2015-09-22 2017-03-29 陕西合成药业股份有限公司 一种分离福司氟康唑或其药用盐有关物质的hplc方法
CN106890167A (zh) * 2015-12-17 2017-06-27 中国科学院上海巴斯德研究所 一种具有抗结核活性的化合物及其应用
US11634666B2 (en) * 2015-12-22 2023-04-25 3M Innovative Properties Company Methods for spore removal comprising a polysorbate surfactant and cationic antimicrobial mixture
KR101749687B1 (ko) 2016-04-25 2017-06-21 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
WO2017188692A1 (ko) * 2016-04-25 2017-11-02 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
KR101792239B1 (ko) 2016-11-01 2017-10-31 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물
CN107184551B (zh) * 2017-06-09 2020-09-01 甘肃新天马制药股份有限公司 一种利拉萘酯双粒径分布乳剂及其制备方法
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CN111658610B (zh) * 2020-07-31 2022-05-24 上海方予健康医药科技有限公司 一种供雾化器用的三氮唑类抗真菌药物的混悬液
CN112791048B (zh) * 2020-12-31 2023-01-17 海南海神同洲制药有限公司 一种硝酸舍他康唑栓及其制备方法
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
CN112931213B (zh) * 2021-03-29 2022-05-27 东北林业大学 一种杨树外植体脱毒试剂、脱毒方法及应用
CN114432297B (zh) * 2022-02-07 2022-10-11 中国人民解放军军事科学院军事医学研究院 Zaragozic acid A在产气荚膜梭菌Epsilon毒素中毒救治中的应用
CN115644062B (zh) * 2022-11-03 2023-11-17 天津科润农业科技股份有限公司 一种提高难出胚大白菜胚诱导率的培养基及其方法
WO2024216151A1 (en) * 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2024216136A1 (en) * 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for the treatment of hematological cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348214A (ja) * 1986-08-18 1988-02-29 Morishita Seiyaku Kk １−〔２−（２，４−ジクロロフエニル）−３−メチル−１−ペンテニル〕−１ｈ−イミダゾ−ルを含有する水中油型脂肪乳剤
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
DE4336434A1 (de) * 1993-10-26 1995-04-27 Hoechst Ag Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
ATE212785T1 (de) * 1996-06-07 2002-02-15 Dsm Nv Verwendung einer fungiziden zusammensetzung als pflanzenschutzmittel
EP0872229A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
KR100635456B1 (ko) * 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
US20030215493A1 (en) * 2002-04-30 2003-11-20 Patel Pravin M. Composition and method for dermatological treatment
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2006029074A2 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
US8633191B2 (en) * 2004-09-21 2014-01-21 Stephen C. Perry Anti-microbial and anti-fungal shampoo for mammals especially humans and dogs
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
CN101273971A (zh) * 2008-05-09 2008-10-01 绍兴文理学院 抗真菌药物的醇质体制剂及其制备方法
CA2731455A1 (en) * 2008-07-23 2010-01-28 Gregor Cevc Methods of administering topical antifungal formulations for the treatment of fungal infections

Also Published As

Publication number Publication date
US20120245107A1 (en) 2012-09-27
WO2010090654A1 (en) 2010-08-12
US20100197621A1 (en) 2010-08-05
ZA201105758B (en) 2013-01-30
CO6410285A2 (es) 2012-03-30
RU2011136624A (ru) 2013-03-10
IL214331A0 (en) 2011-09-27
KR20110128283A (ko) 2011-11-29
SG173183A1 (en) 2011-09-29
CR20110409A (es) 2011-11-02
CN102368998A (zh) 2012-03-07
MX2011008204A (es) 2011-12-06
JP2012516889A (ja) 2012-07-26
EP2393480A1 (en) 2011-12-14
CA2751412A1 (en) 2010-08-12
AU2009339445A1 (en) 2011-08-18
BRPI0924302A2 (pt) 2019-09-24
PE20120326A1 (es) 2012-04-20
NI201100152A (es) 2012-03-28

Similar Documents

Publication Publication Date Title
CR20110409A (es) Metodos para reducir la proliferacion y viabilidad de los agentes microbianos
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
MX342785B (es) Formulacion mejorada de lipido.
ECSP13012877A (es) FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS
UA112086C2 (uk) Гербіцидні композиції, що включають хлорацетаміди
UY35351A (es) Formulaciones acuosas estables de adalimumab
NZ747040A (en) Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
BR112013021509A2 (pt) composições para cuidado pessoal
ECSP11010818A (es) Métodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas
MX2013002382A (es) Composiciones cutaneas y metodos para su uso.
PT2755473T (pt) Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
BR112013013402A2 (pt) combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP11011487A (es) Pirazinilpirazoles
ECSP12011617A (es) Carboxamidas pesticidas
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CR20140505A (es) (r) -nifuratel y sintesis de (r) - nifuratel
CR20150310A (es) Solución para preservar conductos vasculares
EP2575452A4 (en) ANTIMICROBIAL COMPOSITIONS
MY162688A (en) Oral care compositions
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
MX345263B (es) Formulación de pexiganan estable.
BR112013027488A2 (pt) Combinações de substâncias ativas e formulações cosméticas
HK1164749A (en) Methods of reducing the proliferation and viability of microbial agents